Polycystic Ovary Syndrome - Improving Outcomes

• Status: Completed
• Trial end date: 2015-12-01
• Target enrollment: 0
• Participant gender: Female

Summary

Polycystic ovary syndrome affects a striking 9-18% of Australian reproductive aged women and has been associated with a number of metabolic abnormalities.

Given the strong correlation between metabolic abnormalities and increased sympathetic activity, we hypothesise that reducing this activity using medication (moxonidine) can help improve the metabolic abnormalities, and therefore improve outcomes in polycystic ovary syndrome.

• Phase: Phase 4
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Baker Heart and Diabetes Institute; Baker IDI Heart and Diabetes Institute
• Treatments: Moxonidine

Criteria

Inclusion Criteria:

• Overweight and class I obese pre-menopausal women

• Diagnosis of PCOS by Rotterdam criteria

Exclusion Criteria:

• Any current medication

• pregnancy or the desire to become pregnant

• BMI > 35

• a history of type I diabetes, secondary hypertension not due to PCOS

• cardiovascular, cerebrovascular, liver or thyroid disease

• severe mental illness.